)
Edge11 Sep 2026
Texas Pacific Land Corporation: Keeper of the Permian Basin
Land once granted to a failed 19th-century railroad now generates royalties for Texas Pacific Land Corporation across the Permian Basin.
Clearmind Medicine
Clearmind Medicine (CMND) investor relations material
Clearmind Medicine Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary10 Sep, 2026
Executive summary
Engaged in Phase I/IIa clinical trials for non-hallucinogenic, psychedelic-derived neuroplastogens targeting neuropsychiatric, metabolic, and addiction disorders, with a primary focus on Alcohol Use Disorder (AUD).
Advanced clinical trial for CMND-100, with positive safety reviews and progression to higher dose cohorts and additional study parts.
Acquired a 51% stake in Charging Robotics, expanding into intelligent EV wireless charging solutions.
Financial highlights
Cash and cash equivalents as of July 31, 2026: $12.0 million, up from $3.9 million at October 31, 2025.
Net loss for Q3 2026: $0.9 million, improved from $1.3 million in Q3 2025; nine-month net loss: $6.8 million, up from $3.2 million year-over-year.
Operating expenses for Q3 2026: $2.2 million; nine months: $7.4 million.
Finance income for Q3 2026: $1.3 million, driven by changes in warrant liabilities and short-term investments.
Outlook and guidance
Cash position expected to provide liquidity for at least twelve months, but future capital requirements may exceed current resources depending on clinical trial progress.
Continued dependence on external financing for ongoing operations and program advancement.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Clearmind Medicine
- Q1 2026 saw a $3.85M net loss, higher expenses, and a strengthened cash position.CMND
Q1 2026 - Clinical trials advanced, net loss widened, cash position strengthened via new financings.CMNDQ2 2026
- Psychedelic drug developer seeks $10M convertible note to fund trials, enabling resale of up to 22.6M shares.CMNDRegistration filing
- Novel psychedelic AUD therapy in clinical trials, funded by convertible notes, faces dilution and geopolitical risks.CMNDRegistration Filing
- Net loss narrowed, but ongoing losses, no revenue, and funding needs raise going concern risk.CMNDQ4 2025
- Developing psychedelic therapies for AUD and obesity, but faces ongoing losses and high risk.CMNDRegistration Filing
- Registering up to 17M shares for resale, funding R&D of non-hallucinogenic psychedelic therapies.CMNDRegistration Filing
- Psychedelic drug developer registers resale of 5.78M shares amid clinical trials and compliance risks.CMNDRegistration Filing
- Clinical trials advanced, net loss narrowed, but future financing remains critical.CMNDQ3 2025
Next Clearmind Medicine earnings date
Q4 202621 Jan, 2027
Clearmind Medicine
Next Clearmind Medicine earnings date
Q4 202621 Jan, 2027
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage